Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Biopharma Resilience | Gilead maintains a robust HIV market presence, with strategic oncology ventures despite some trial setbacks. |
Valuation Spectrum | Analysts set Gilead's price targets between $74-$80, reflecting confidence in its long-term growth potential. |
Market Contenders | Gilead's innovative strategies in GLP-1 and antivirals aim to strengthen its position against intense biopharma competition. |
Growth Trajectory | Gilead's disciplined capital management and promising pipeline poise it for expansion in infectious diseases and oncology. |
Metrics to compare | GILD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILDPeersSector | |
---|---|---|---|---|
P/E Ratio | 106.1x | −2.6x | −0.6x | |
PEG Ratio | −1.31 | −0.01 | 0.00 | |
Price/Book | 6.1x | 2.1x | 2.6x | |
Price / LTM Sales | 4.0x | 11.6x | 3.2x | |
Upside (Analyst Target) | 0.5% | 163.2% | 48.6% | |
Fair Value Upside | Unlock | 17.2% | 7.0% | Unlock |